[Analysis of the safety and efficacy of 60 mg·m<sup>-2</sup>·d<sup>-1</sup>daunorubicin combined with standard dose of cytarabine as induction therapy in acute myeloid leukemia patients under 65 years old].

Cao, X X; Wang, S J; Duan, M H; Zhu, T N; Zhang, W; Han, B; Zhuang, J L; Cai, H C; Chen, M; Feng, J; Han, X; Zhang, Y; Yang, C; Zhang, L; Zhou, D B; Li, J

[Analysis of the safety and efficacy of 60 mg·m^-2·d^-1daunorubicin combined with standard dose of cytarabine as induction therapy in acute myeloid leukemia patients under 65 years old].

Cao, X X; Wang, S J; Duan, M H; Zhu, T N; Zhang, W; Han, B; Zhuang, J L; Cai, H C; Chen, M; Feng, J; Han, X; Zhang, Y; Yang, C; Zhang, L; Zhou, D B; Li, J.

Afiliación

Cao XX; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

Zhonghua Xue Ye Xue Za Zhi ; 37(10): 892-897, 2016 Oct 14.

Article en Zh | MEDLINE | ID: mdl-27801323

Asunto(s)

Leucemia Mieloide Aguda/tratamiento farmacológico; Protocolos de Quimioterapia Combinada Antineoplásica; Citarabina; Daunorrubicina; Supervivencia sin Enfermedad; Humanos; Terapia Neoadyuvante; Inducción de Remisión; Estudios Retrospectivos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2016 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google